Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 21 December 1990:
Vol. 250. no. 4988, pp. 1707 - 1708
DOI: 10.1126/science.2270484
Prev | Table of Contents | Next

Articles

Science, Vol 250, Issue 4988, 1707-1708
Copyright © 1990 by American Association for the Advancement of Science

articles

Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome

AN Mayeno, F Lin, CS Foote, DA Loegering, MM Ames, CW Hedberg, and GJ Gleich

Epidemiologic studies strongly associate eosinophilia-myalgia syndrome (EMS) with ingestion of tryptophan containing a contaminant ("peak E"). Prior reports have suggested that peak E is the di-tryptophan N alpha-animal of acetaldehyde. Spectral and chemical studies now demonstrate that peak E is 1,1'-ethylidenebis[tryptophan]. This novel amino acid may be the etiological agent responsible for EMS, or it may be a marker of a still unidentified causal agent.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effect of L-Tryptophan Supplementation on Eosinophils and Eotaxin in Guinea Pigs.
J. L. Stahl, E. B. Cook, M. A. Pariza, M. E. Cook, and F. M. Graziano (2001)
Experimental Biology and Medicine 226, 177-184
   Abstract »    Full Text »
Dot-like focal contacts in adherent eosinophils, their redistribution into peripheral belts, and correlated effects on cell migration and protected zone formation.
A Tourkin, M Bonner, E Mantrova, E. LeRoy, and S Hoffman (1996)
J. Cell Sci. 109, 2169-2177
   Abstract »    PDF »
The Stress Response and the Regulation of Inflammatory Disease.
E. M. Sternberg, G. P. Chrousos, R. L. Wilder, and P. W. Gold (1992)
Ann Intern Med 117, 854-866
   Abstract »    PDF »
The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome.
J. Varga, J. Uitto, and S. A. Jimenez (1992)
Ann Intern Med 116, 140-147
   Abstract »    PDF »
Eosinophilia-Myalgia Syndrome in L-Tryptophan--Exposed Patients.
M. L. Kamb, J. J. Murphy, J. L. Jones, J. C. Caston, K. Nederlof, L. F. Horney, L. A. Swygert, H. Falk, and E. M. Kilbourne (1992)
JAMA 267, 77-82
   Abstract »    PDF »
Effect of Benzodiazepines on Tryptophan Binding to Rat Hepatic Nuclei.
H. Sidransky, E. Verney, J. W. Cosgrove, and A. M. Schwartz (1992)
Toxicol Pathol 20, 350-356
   Abstract »    PDF »
Natural History of the Eosinophilia-Myalgia Syndrome.
R. C. Culpepper, R. G. Williams, P. J. Mease, T. D. Koepsell, and J. M. Kobayashi (1991)
Ann Intern Med 115, 437-442
   Abstract »    PDF »
Unraveling the Eosinophilia-Myalgia Syndrome.
R. M. Silver (1991)
Arch Dermatol 127, 1214-1216
   Abstract »    PDF »
Postmortem Studies of the Heart in Three Fatal Cases of the Eosinophilia-Myalgia Syndrome.
T. N. James, M. L. Kamb, G. A. Sandberg, R. M. Silver, and E. M. Kilbourne (1991)
Ann Intern Med 115, 102-110
   Abstract »    PDF »
Clinical Pharmacology.
M. M. Reidenberg (1991)
JAMA 265, 3107-3109
   Abstract »    PDF »
A new cofactor in a prokaryotic enzyme: tryptophan tryptophylquinone as the redox prosthetic group in methylamine dehydrogenase.
W. McIntire, D. Wemmer, A Chistoserdov, and M. Lidstrom (1991)
Science 252, 817-824
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)